cicimetinib

Cicimetinib (SIM0235) is an orally bioavailable, highly selective, and potent small molecule inhibitor of the mitogen-activated protein kinase kinases 1 and 2 (MEK1/2). Developed by the Shanghai Institute of Materia Medica (SIMM) in collaboration with Shanghai Runshi Pharmaceutical, cicimetinib targets the MAPK/ERK signaling pathway, which is frequently dysregulated in various human cancers, particularly those harboring RAS or BRAF mutations. By inhibiting MEK1/2, the drug blocks downstream signaling that promotes cell proliferation and survival. Cicimetinib is currently being evaluated in Phase I/II clinical trials in China, both as a monotherapy and in combination with the anti-PD-1 monoclonal antibody SG001, for the treatment of advanced, unresectable, or recurrent solid tumors.

Other names

cicimetinib hydrochloride盐酸希美替尼